<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3115">
  <stage>Registered</stage>
  <submitdate>18/03/2011</submitdate>
  <approvaldate>18/03/2011</approvaldate>
  <nctid>NCT01319487</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy</studytitle>
    <scientifictitle>A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FOV2304/CLIN/201/P</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Macular Edema</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - 2304 Eye Drops High Dose
Treatment: drugs - 2304 Eye Drops Low Dose
Treatment: drugs - Placebo Eye Drops

Experimental: 2304 Eye Drops High Dose - 2304 Eye Drops High Dose self-administered in the study eye during the treatment period

Experimental: 2304 Eye Drops Low Dose - 2304 Eye Drops Low Dose self-administered in the study eye during the treatment period

Placebo Comparator: Placebo Eye Drops - Placebo Eye Drops self-administered in the study eye during the treatment period


Treatment: drugs: 2304 Eye Drops High Dose
2304 Eye Drops High Dose self-administered in the study eye during the treatment period

Treatment: drugs: 2304 Eye Drops Low Dose
2304 Eye Drops Low Dose self-administered in the study eye during the treatment period

Treatment: drugs: Placebo Eye Drops
Placebo Eye Drops self-administered in the study eye during the treatment period

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>change from baseline of central retinal thickness as determined by logOCT</outcome>
      <timepoint>Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with an improvement in best corrected visual acuity (BCVA)</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in macular volume and retinal thickness from baseline to Week 12 and Week 24</outcome>
      <timepoint>Baseline, Week 12, Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Main inclusion/exclusion criteria are listed below. Others may apply.

        

          1. Male or female, at least 18 years of age.

          2. Diagnosis of diabetes mellitus

          3. Patient must be able to self administer study drug.

          4. Clinically significant diabetic macular edema in at least one eye ("study eye")
             involving the center of the macula:

          5. Mild to severe non proliferative diabetic retinopathy (Early Treatment Diabetic
             Retinopathy Study [ETDRS] grade between 20 and 53).

          6. BCVA score = 34 letters and &lt; 80 letters in the study eye.

          7. Women of childbearing potential must have a negative urine pregnancy test at Screening
             and be using two highly effective methods of contraception throughout the study.

          8. Male patients with partners of childbearing potential must agree to use at least one
             highly effective method of contraception throughout the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Ocular conditions:

          1. Any ocular condition in the study eye that in the opinion of the investigator would
             prevent improvement in visual acuity.

          2. Proliferative diabetic retinopathy in the study eye.

          3. History of panretinal scatter photocoagulation(PRP)in the study eye within 4 months
             prior to screening, and/or anticipated need for PRP in the 3 months following
             randomization.

          4. Active optic disc or retinal neovascularization, rubeosis iridis, active or history of
             choroidal neovascularization in the study eye.

          5. History of pars plana vitrectomy at any time, intraocular surgery in the study eye
             within 90 days prior to screening.

          6. History of use of intravitreal injectable or periocular depots corticosteroids (other
             than triamcinolone acetonide)within 3 months prior to the screening visit in the study
             eye.

          7. Patients who have previously received triamcinolone acetonide in the study eye:

               -  The intended dose for each triamcinolone acetonide injection was more than 4 mg.

               -  The most recent dose was less than 3 months prior to the screening visit.

               -  Any treatment-related adverse event that was seen, and in the opinion of the
                  investigator, has the potential to worsen or reoccur with study treatment.

          8. Patients who have previously received anti-VEGF therapy within 3 months prior to the
             screening visit in the study eye.

          9. Uncontrolled glaucoma or glaucoma treated by 2 or more medications.

         10. Aphakia or intraocular lens placement in the anterior chamber of the study eye.

         11. Any active ocular infection; any history of recurrent or chronic infection or
             inflammation in the study eye.

         12. History of herpetic infection in either eye.

         13. History of corneal pathology/surgery

         14. Contact lens use at any time during the study.

             Systemic conditions:

         15. Uncontrolled systemic disease.

         16. Poorly controlled diabetes mellitus.

         17. Impaired renal function

         18. Poorly controlled arterial hypertension</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>267</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Center 2003 - Chatswood</hospital>
    <hospital>Center 2002 - Melbourne</hospital>
    <hospital>Center 2004 - Murdoch</hospital>
    <hospital>Center 2001 - Sydney</hospital>
    <postcode> - Chatswood</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Murdoch</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Wilrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Zlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ahaus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Darmstadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Karlsruhe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Saarbruecken</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Afula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Sheva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Yakov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar-Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Saronno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Oviedo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago de Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valladolid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Fovea Pharmaceuticals SA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low
      dose) administered in the eye are more effective than placebo in treating patients with
      diabetic macular edema, following 12 weeks of treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01319487</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pascale Massin, MD</name>
      <address>Lariboisière Hospital, Paris</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>